The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

An important milestone for the potential use of mesenchymal stem cells in MS. This phase 1 study demonstrates that it is feasible to harvest these stems cells from the skin of PwMS, expand them in the laboratory and give them back to patients safely. In addition, the investigators did this in away that could be used to assess their effectiveness in larger, placebo-controlled, double-blinded, phase 2 studies.

“Well done guys!”

Connick et al. Trials. 2011 Mar 2;12:62.

Leave a Reply

%d bloggers like this: